A pharmaceutical company develops a second-generation version of an antihistamine that prevents seasonal allergy symptoms (sneezing, itchy, runny nose and watery eyes). The advantage of the new version is that, unlike the first-generation drug, it does not cause central nervous system side effects, such as sedation and dizziness. Both drugs are taken orally. Compared to the older antihistamine, the second-generation agent has a low degree of:
Wähle eine der folgenden: